title: Differential regulation of uncoupling proteins by chronic treatments with beta 3-adrenergic agonist BRL 35135 and metformin in obese fa/fa Zucker rats.
abstract: The expressions of uncoupling proteins 2 and 3 (UCP2; UCP3) mRNA were studied in obese (fa/fa) Zucker rats treated with two weight gain reducing agents for three weeks. The specific beta 3-adrenoceptor agonist BRL 35135 (0.5 mg/kg/day orally) increased the expression of UCP3 mRNA by 3.8-fold (P < 0.0001; two-way ANOVA) and that of UCP1 mRNA by 2.6-fold (P = 0.014) in brown adipose tissue, but had no effect on expression of UCP3 mRNA in white fat or in the soleus muscle, or on UCP2 mRNA expression in brown or white fat. The antihyperglycemic metformin (300 mg/kg/day orally) had no effect on expressions of UCP1, UCP2 or UCP3 in any tissue studied. Concentrations of plasma insulin were significantly correlated with the levels of white fat UCP2 mRNA (in the control group: r = 0.89, P = 0.0015) and UCP3 mRNA (in the control group: r = 0.80, P = 0.009) suggesting that insulin may play a role in the control of UCP2 and UCP3 mRNA expressions in white adipose tissue.
authors.affiliation: Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland. erisan@utu.fi
authors.forename: E
authors.initials: E
authors.lastname: Savontaus
authors.forename: J
authors.initials: J
authors.lastname: Rouru
authors.forename: O
authors.initials: O
authors.lastname: Boss
authors.forename: R
authors.initials: R
authors.lastname: Huupponen
authors.forename: M
authors.initials: M
authors.lastname: Koulu
mesh_terms: D000273:Adipose Tissue / Q000378:metabolism; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000704:Analysis of Variance; D000818:Animals; D002352:Carrier Proteins / Q000096:biosynthesis*; D004435:Eating / Q000187:drug effects; D004702:Endocrine Glands / Q000378:metabolism; D004734:Energy Metabolism; D005786:Gene Expression Regulation; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D007473:Ion Channels; D020738:Leptin; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis*; D026901:Membrane Transport Proteins; D008687:Metformin / Q000494:pharmacology; D024101:Mitochondrial Proteins; D018482:Muscle, Skeletal / Q000378:metabolism; D009765:Obesity / Q000378:metabolism*; D010627:Phenethylamines / Q000494:pharmacology*; D014176:Protein Biosynthesis; D011506:Proteins / Q000032:analysis; D051381:Rats; D011924:Rats, Zucker; D011943:Receptors, Adrenergic, beta / Q000378:metabolism*; D022702:Receptors, Adrenergic, beta-3; D014475:Uncoupling Agents; D000071256:Uncoupling Protein 1; D000071246:Uncoupling Protein 2; D000071247:Uncoupling Protein 3; D015430:Weight Gain / Q000187:drug effects
chemical_list: D000318:Adrenergic beta-Agonists; D002352:Carrier Proteins; D007004:Hypoglycemic Agents; D007328:Insulin; D007473:Ion Channels; D020738:Leptin; D008565:Membrane Proteins; D026901:Membrane Transport Proteins; D024101:Mitochondrial Proteins; D010627:Phenethylamines; D011506:Proteins; D011943:Receptors, Adrenergic, beta; D022702:Receptors, Adrenergic, beta-3; C000604373:Ucp1 protein, rat; C000604391:Ucp2 protein, rat; C000604394:Ucp3 protein, rat; D014475:Uncoupling Agents; D000071256:Uncoupling Protein 1; D000071246:Uncoupling Protein 2; D000071247:Uncoupling Protein 3; D008687:Metformin; C063157:BRL 35135